These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38346840)

  • 1. Danavorexton (TAK-925): an orexin receptor 2 agonist as a new 'arousal' agent.
    Lambert DG; Hirota K
    Br J Anaesth; 2024 Mar; 132(3):466-468. PubMed ID: 38346840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys.
    Suzuki M; Shiraishi E; Cronican J; Kimura H
    Br J Anaesth; 2024 Mar; 132(3):541-552. PubMed ID: 38296753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
    Ishikawa T; Hara H; Kawano A; Kimura H
    Pharmacol Biochem Behav; 2022 Oct; 220():173464. PubMed ID: 36108771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
    Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
    J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals.
    Evans R; Kimura H; Nakashima M; Ishikawa T; Yukitake H; Suzuki M; Hazel J; Faessel H; Wu J; Hang Y; Alexander R; Rosen L; Hartman DS; Ratti E
    J Sleep Res; 2023 Oct; 32(5):e13878. PubMed ID: 36934366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
    Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
    Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of orexin (hypocretin) on GIRK channels.
    Hoang QV; Bajic D; Yanagisawa M; Nakajima S; Nakajima Y
    J Neurophysiol; 2003 Aug; 90(2):693-702. PubMed ID: 12702704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia.
    Mignot E; Bogan RK; Emsellem H; Foldvary-Schaefer N; Naylor M; Neuwirth R; Faessel H; Swick T; Olsson T
    Sleep; 2023 Sep; 46(9):. PubMed ID: 36883238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexins/hypocretins: pain regulation and cellular actions.
    Chiou LC; Lee HJ; Ho YC; Chen SP; Liao YY; Ma CH; Fan PC; Fuh JL; Wang SJ
    Curr Pharm Des; 2010; 16(28):3089-100. PubMed ID: 20687883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats.
    Matzeu A; Martin-Fardon R
    Neuropharmacology; 2020 Mar; 164():107906. PubMed ID: 31841797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP.
    Bogan RK; Maynard JP; Neuwirth R; Faessel H; Swick T; Olsson T
    Sleep Med; 2023 Jul; 107():229-235. PubMed ID: 37244138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
    Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
    Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray.
    Lee HJ; Chang LY; Ho YC; Teng SF; Hwang LL; Mackie K; Chiou LC
    Neuropharmacology; 2016 Jun; 105():577-586. PubMed ID: 26907809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanil.
    Porter-Stransky KA; Bentzley BS; Aston-Jones G
    Addict Biol; 2017 Mar; 22(2):303-317. PubMed ID: 26598295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys.
    Yamada R; Narita N; Ishikawa T; Kakehi M; Kimura H
    Pharmacol Biochem Behav; 2024 Jan; 234():173690. PubMed ID: 38061670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orexin-1 Receptor Signaling in Ventral Pallidum Regulates Motivation for the Opioid Remifentanil.
    Mohammadkhani A; Fragale JE; Pantazis CB; Bowrey HE; James MH; Aston-Jones G
    J Neurosci; 2019 Dec; 39(49):9831-9840. PubMed ID: 31641055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord.
    Hervieu GJ; Cluderay JE; Harrison DC; Roberts JC; Leslie RA
    Neuroscience; 2001; 103(3):777-97. PubMed ID: 11274794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orexins and appetite regulation.
    Rodgers RJ; Ishii Y; Halford JC; Blundell JE
    Neuropeptides; 2002 Oct; 36(5):303-25. PubMed ID: 12450737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optogenetic examination identifies a context-specific role for orexins/hypocretins in anxiety-related behavior.
    Heydendael W; Sengupta A; Beck S; Bhatnagar S
    Physiol Behav; 2014 May; 130():182-90. PubMed ID: 24140988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between Orexin Neurons and Monoaminergic Systems.
    Sakurai T; Saito YC; Yanagisawa M
    Front Neurol Neurosci; 2021; 45():11-21. PubMed ID: 34052806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.